Drug Profile
Tezepelumab - Amgen/AstraZeneca
Alternative Names: AMG 157; MEDI-9929; Tezepelumab-ekko; TezspireLatest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; AstraZeneca
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Phase III Eosinophilic oesophagitis; Rhinosinusitis
- Phase II Chronic obstructive pulmonary disease; Chronic urticaria
- Discontinued Atopic dermatitis
Most Recent Events
- 31 Jan 2024 AstraZeneca completes a phase II COURSE trial in Chronic obstructive pulmonary disease (Treatment-experienced, In adults, In the elderly) in Canada, Denmark, France, Germany, Israel, the Netherlands, Spain, South Korea, United Kingdom, USA(SC) (NCT04039113)
- 09 Sep 2023 Efficacy results from phase III DESTINATION trial in Asthma presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 09 Sep 2023 Efficacy data from the phase III NAVIGATOR trial in Asthma presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)